Professor Pnina Fishman, Chief Executive Officer at Can-Fite BioPharma, an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer and inflammatory diseases.

She is joining eHealth Radio and the Health News, Cancer Prevention and Skin Care Channels to discuss a common skin condition affecting millions around the world: Psoriasis. August happens to be National Psoriasis Awareness Month.

Why do topical treatments for psoriasis not seem to eradicate the condition?

Why are existing oral and biological drugs only reserved as a last resort for patients? Do the risks of these drugs outweigh the benefits?

What can small molecule drugs do for the condition? How do they work?

How do small molecule drugs differ from other oral and biologics in the market? How safe are they?

How long before we see CF101 in the market?

Duration: 8:05

Prof. Pnina Fishman is the scientific founder of the company and was previously a professor of Life Sciences and headed the Laboratory of Clinical and Tumor Immunology at the Felsenstein Medical Research Institute, Rabin Medical Center.

Prof. Fishman is a very accomplished scientist and has authored or co-authored over 150 publications and presented the findings of her research at many major scientific meetings. Her scientific work was the foundation on which Can-Fite was built.

Can-Fite BioPharma Ltd. is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer and inflammatory diseases. The Company's CF101 is in Phase II/III trials for the treatment of psoriasis and the Company is preparing for a Phase III CF101 trial for rheumatoid arthritis.

Can-Fite's liver cancer drug CF102 is commencing Phase II trials and has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. CF102 has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. These drugs have an excellent safety profile with experience in over 1,200 patients in clinical studies to date.